Results 11 to 20 of about 1,565,191 (184)
Ferulic acid as a therapeutic agent in depression: Evidence from preclinical studies
CNS Neuroscience &Therapeutics, Volume 29, Issue 9, Page 2397-2412, September 2023., 2023 Abstract Depression is a common but severe mood disorder with a very high prevalence across the general population. Depression is of global concern and poses a threat to human physical and mental health. Ferulic acid (FA) is a natural active ingredient that has antioxidative, anti‐inflammatory, and free radical scavenging properties.
Xiaoyu Dong, Dongxue Zhao
wiley +1 more source
iMeta, Volume 2, Issue 3, August 2023., 2023 We successfully isolated Maca‐EVs using ultracentrifugation and tested its antidepressant effects in the unpredictable chronic mild stress mice. Maca‐EVs increased serum serotonin (5‐HT) levels probably via the gut microbiota and metabolism modulation.
Rui Hong +14 more
wiley +1 more source
Increased risk of depression after Guillain‐Barré syndrome
Muscle &Nerve, Volume 67, Issue 6, Page 497-505, June 2023., 2023 Abstract Introduction/Aims Guillain‐Barré syndrome (GBS) is a potentially life‐threatening disorder, and some patients may develop subsequent depression related to traumatic stress or permanent loss of motor function. We determined the short‐term (0 to 2 years) and long‐term (>2 years) risk of depression after GBS.
Lotte Sahin Levison +2 more
wiley +1 more source
Novel drug developmental strategies for treatment‐resistant depression
British Journal of Pharmacology, Volume 179, Issue 6, Page 1146-1186, March 2022., 2022 Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment‐resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1) knowledge of pathophysiology, (2) translational ...
Éva Borbély +5 more
wiley +1 more source
Antidepressant use and stroke or mortality risk in the elderly
European Journal of Neurology, Volume 29, Issue 2, Page 469-477, February 2022., 2022 In real‐world data of the elderly population, it was found that the risk of experiencing stroke or death in antidepressant users during and up to 1 year after exposure was higher compared to non‐users, even after adjustment for possible confounders. Abstract Background and purpose Current evidence on antidepressant‐related stroke or mortality risk is ...
Begüm Irmak Ön +7 more
wiley +1 more source
Overdoses with Tricyclic Antidepressants
, 1976 The authors present a 46-year-old female and a 14-month-old female following ingestion of an overdose of tricyclic antidepressants, amitriptyline and imipramine, respectively.
Judith A. Ludy +4 more
core +1 more source
The use of low dose tricyclic antidepressants at Heideveld Community Health Centre [PDF]
, 2004 Includes bibliographical references.AIM OF THIS STUDY: To describe how doctors are prescribing low dose antidepressants at Heideveld Community Health Centre. OBJECTIVES: 1.
Banderker, Shahida
core +1 more source
Reboxetine versus other antidepressive agents for depression
, 2009 Reboxetine versus other antidepressive agents for ...
CIPRIANI, Andrea +15 more
core +1 more source
Milnacipran versus other antidepressive agents for depression.
, 2009 BACKGROUND: Although pharmacological and psychological interventions are both effective for major depression, antidepressant drugs are frequently used as first-line treatment in primary and secondary care settings.
McGuire, H +14 more
core +1 more source
Correlation of antidepressive agents and the mortality of end-stage renal disease
, 2012 [[abstract]]Aim:Depression is one of the most common psychological disorders in end-stage renal disease (ESRD) patients and is associated with impaired quality of life and increased mortality and rate of hospitalization.
Tsai, CJ;Loh, EW;Lin, CH;Yu, TM;Chan, CH;Lan, TH
core +1 more source